Clostridium difficileinfection: update on emerging antibiotic treatment options and antibiotic resistance

In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

(2010) Z-D Jiang et al.   JOURNAL OF CLINICAL PATHOLOGY

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

(2009) D.M. Citron et al.   ANAEROBE

Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with Rifaximin immediately post-vancomycin treatment

(2009) Stuart Johnson et al.   ANAEROBE

Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe RefractoryClostridium difficileInfection

(2009) Bjorn L. Herpers et al.   CLINICAL INFECTIOUS DISEASES

Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study

(2009) Daniel M. Musher et al.   CLINICAL INFECTIOUS DISEASES

High Frequency of Rifampin Resistance Identified in an EpidemicClostridium difficileClone from a Large Teaching Hospital

(2009) Scott R. Curry et al.   CLINICAL INFECTIOUS DISEASES

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)

(2009) M.P. Bauer et al.   CLINICAL MICROBIOLOGY AND INFECTION

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI)

(2009) M.J.T. Crobach et al.   CLINICAL MICROBIOLOGY AND INFECTION

Antimicrobial resistance in Clostridium difficile

(2009) Haihui Huang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors

(2009) F. Sundram et al.   JOURNAL OF HOSPITAL INFECTION

Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora

(2008) S. M. Finegold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile

(2008) J. R. O'Connor et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile

(2008) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

(2008) T. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control

(2008) Herbert L DuPont et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Tigecycline

(2008) Kate McKeage et al.   DRUGS

Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer

(2008) Karl Weiss   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study

(2008) Kevin W. Garey et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Clostridium difficile— More Difficult Than Ever

(2008) Ciarán P. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE